US20080126195A1 - Methods and Compositions for Treating Lactose Intolerance - Google Patents
Methods and Compositions for Treating Lactose Intolerance Download PDFInfo
- Publication number
- US20080126195A1 US20080126195A1 US11/632,289 US63228905A US2008126195A1 US 20080126195 A1 US20080126195 A1 US 20080126195A1 US 63228905 A US63228905 A US 63228905A US 2008126195 A1 US2008126195 A1 US 2008126195A1
- Authority
- US
- United States
- Prior art keywords
- lactose
- symptoms
- treatment
- bacteria
- grams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
- A23L27/33—Artificial sweetening agents containing sugars or derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/02—Marketing; Price estimation or determination; Fundraising
- G06Q30/0207—Discounts or incentives, e.g. coupons or rebates
- G06Q30/0212—Chance discounts or incentives
Definitions
- Lactose is not digested when the amount of lactose consumed exceeds the lactase enzyme capacity of the small intestine. Instead, excess undigested lactose passes through the small intestines into the large intestine where it is fermented by a bacteria called colinic flora. The fermentation of the lactose in the large intestine produces hydrogen and methane which can lead to bloating, gas, and diarrhea. These symptoms are caused by a very low activity of lactase in the intestines.
- lactose intolerance The reasons for an onset of lactose intolerance are generally unknown. However, there is a general belief that by consuming small amounts of lactose frequently over a period of time, lactose intolerance can be improved. Whole milk and chocolate milk appear to be tolerated better than low fat milk because the fat content of whole milk and chocolate milk slows the rate of gastric emptying. Previous attempts at improving the symptoms of lactose intolerance have met with some success. See, e.g., Published U.S. Patent Application No. 0020034496 The present invention builds upon this previous success.
- the invention provides methods, compositions, kits, and business methods for the reduction of symptoms of lactose intolerance.
- Symptoms of lactose intolerance include gas, bloating, diarrhea, abdominal pain, cramping, and vomiting.
- the methods and compositions of the invention reduce or eliminate one or more of these symptoms, typically all of the symptoms.
- a striking aspect of the present invention is that the reduction or elimination of symptoms persists after treatment has concluded. Thus, the present invention need not be used on a continuous basis but rather may be utilized in a discrete time period and then discontinued.
- Lactose Intolerance otherwise referred to as lactose maldigestion, is the inability to digest a significant amount of lactose, derived from a deficiency of the lactase enzyme in the small intestine.
- Lactose is the natural sugar in milk and milk products of all mammals.
- Lactase is the enzyme which splits the milk sugar lactose into its components (i.e., glucose and galactose), and also breaks down the milk sugar into smaller forms that can be processed into the bloodstream.
- the lactase enzyme is necessary for mammals to digest lactose.
- lactose intolerance is the inability of the body to digest lactose-containing products due to a deficiency in the lactase enzyme.
- a milk allergy is a sensitively to the protein in milk, which involves the immune system and does not relate to a deficiency of the lactase enzyme. In humans, a milk allergy is usually experienced only by infants.
- the primary cause is an onset of loss of lactase that is a permanent condition. This occurs at a variable period after the weaning period.
- the primary cause is also genetically determined.
- the secondary cause is generally a temporary condition that occurs as a result of another disease or event that damages the lining of the small intestine where lactase is active. This is usually caused by an acute diarrheal disease, parasitic infection, Cohn's disease, celiac disease, gastrointestinal surgery, or the intake of certain medications.
- lactose intolerance In addition to the primary and secondary causes, certain human ethnic and racial populations have more of a predisposition for lactose intolerance. In these populations, social and cultural habits and attitudes influence lactose intolerance. Lactose activity can also decrease with age in certain ethnic and racial populations, including those populations which have origins in Europe, the African plains, and the Siberian Steppes. Humans who are most likely to have or develop lactose intolerance include those of Asian, Middle Eastern, North American, African, and Latin American decent.
- Lactose intolerance can be tested either indirectly or directly.
- a hydrogen breath test the breath is measured to determine the amount of hydrogen produced after consuming a measured amount of lactose, typically 15 g.
- the lactose is consumed by drinking a lactose mixture, and the subject exhales into a vacuum-sealed collection tube at three one hour time intervals.
- a high level of hydrogen in the breath indicates an improper digestion of lactose.
- the stool test the stool is tested to determine the amount of acid.
- a blood glucose test the blood is tested to determine the amount of glucose (sugar) content after administering a predetermined amount of lactose-containing product to the subject.
- the direct method measures lactose activity in a mucosal biopsy specimen.
- Lactose intolerance may also be psychologically induced. There are also many different variations of lactose intolerance depending on the individual. For example, some individuals cannot have cheese, melted cheese, plain milk, or warm diary containing products like milk in coffee, while others cannot have any diary products at all. Also, most lactose intolerant people are limited as to the amount of special “lactose free” foods they can eat that have been manufactured by specified companies. Some examples of these “lactose free” foods are: Mocha Mix ice cream, Tofutti ice cream and ice cream sandwiches, LACTAID® brand milk, cheese, Tofutti “Better than Cream Cheese”, margarine, and live cultured yoghurt. These products are not readily available everywhere.
- lactase tablets help lactose intolerant people digest milk and milk products.
- Each lactase tablet typically hydrolyzes up to 99% of the ingested lactose within 24 hours, and is designed to be ingested with the lactose containing food.
- Methods of the invention include methods of administering lactose in increasing doses to an individual suffering from lactose intolerance. The end result is a reduction or elimination of the symptoms of lactose intolerance in the individual. Methods include the administration of lactose, in increasing doses, for a period of time, to an individual with lactose intolerance.
- the lactose may be in any form, including liquid or powdered. In some embodiments, other substances are administered in combination with the lactose.
- “In combination,” as used herein, encompasses simultaneous administration of a substance with lactose, as well as administration before lactose (e.g., before a regimen of increasing doses of lactose begins, or before a dose of lactose during such a regimen), after lactose (e.g., after a regimen of increasing doses of lactose begins, or after a dose of lactose during such a regimen), or any combination thereof.
- Other substances of use in the methods and compositions of the invention besides lactose include live bacteria, fructooligosaccharides, and buffers, e.g., phosphates.
- Methods of the invention also include the administration of lactose in increasing doses, in combination with other treatments for lactose intolerance.
- Other treatments include any of those described herein, such as the use of lactase, or the use of products containing pre-digested lactose.
- the invention further provides methods of decreasing the symptoms of lactose intolerance for an extended period of time after treatment stops.
- the methods of the invention include partially, substantially, or completely decreasing the symptoms of lactose intolerance for a period of days, weeks, months, years, or permanently. Such a decrease is accomplished by the methods and compositions described herein.
- lactose intolerance Individuals who may benefit from the methods and compositions of the invention include individuals suffering from the symptoms of lactose intolerance, as described above. Any degree of lactose intolerance may be treated by the methods of the invention. Symptoms of lactose intolerance include gas, bloating, abdominal discomfort, diarrhea, vomiting, and/or cramping. Effectiveness of treatment may be measured in a number of ways. Conventional measurements, such as hydrogen gas production, stool acidity, or blood glucose, may be used before and after treatment. Alternatively, or in addition, the amount of lactose-containing product that may be consumed before the onset of one or more symptoms may be measured or evaluated before and after treatment. Thus, for example, treatment is considered partially effective if, after treatment, on average less hydrogen is produced with a given dose of lactose.
- “Partial” elimination of symptoms of lactose intolerance is any noticeable or measurable increase in the amount of lactose that may be consumed before the onset of symptoms. “Substantial” elimination of symptoms of lactose intolerance, as used herein, encompasses an effect where at least about twice the amount of lactose may be consumed after treatment before the onset of symptoms as could have been consumed before treatment.
- “Complete” or “substantially complete” elimination of symptoms of lactose intolerance indicates that normal amounts of lactose may be consumed after treatment (i.e., the amount of lactose in a typical diet for the area and/or culture in which the individual normally lives) without symptoms, or with only the rare occurrence of symptoms.
- an individual may know that if he or she consumes one half cup (4 oz.) of milk that there will be no, or minimal, symptoms, but if 1 or more cup of milk is consumed, then symptoms such as gas or diarrhea occur. The individual may find that, after treatment, 1 and one-half cups of milk may be consumed but that 3 or more cups cause symptoms.
- effectiveness may be measured by percent decrease in symptoms of lactose intolerance.
- the severity of a predetermined symptom, or set of symptoms is measured before and after treatment, e.g., using pre and post Likert scale.
- Exemplary symptoms include gas, bloating, diarrhea, cramping, abdominal pain, and vomiting. Any one, or more than one, of the symptoms may be measured. For example, an individual may be asked to rate one or more symptoms on a scale of increasing severity from 1 to 5. In one embodiment, a set of symptoms is rated, and the ratings are added; for example, gas, bloating, diarrhea, abdominal pain, and cramping may b rated.
- Percentage decrease in symptoms from before to after treatment may be calculated, and the symptoms of lactose intolerance may be considered eliminated by that percent decrease (e.g., if there is a 50% decrease in symptoms, then symptoms of lactose intolerance is 50% eliminated). See, e.g., Example 2.
- the invention provides a method of decreasing symptoms of lactose intolerance in an individual exhibiting symptoms of lactose intolerance by administering to the individual increasing amounts of lactose for a period of time, wherein one or more symptoms of lactose intolerance are partially, substantially, or completely eliminated.
- the symptom(s) of lactose intolerance remains partially, substantially, or completely eliminated for at least about 1 day, 1 week, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 9 months, one year, 18 months, two years, three years, four years, five years, or more than five years after the termination of treatment, or permanently after the termination of treatment.
- the invention provides a method of decreasing symptoms of lactose intolerance in an individual exhibiting symptoms of lactose intolerance by administering to the individual increasing amounts of lactose for a period of time, wherein symptoms of lactose intolerance are substantially eliminated for at least about one month after treatment is terminated.
- the invention provides a method of decreasing symptoms of lactose intolerance in an individual exhibiting symptoms of lactose intolerance by administering to the individual increasing amounts of lactose for a period of time, wherein the symptoms of lactose intolerance, measured as described herein, are decreased by an average of about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100%.
- An “average” decrease is a decrease as measured in a group of individuals exhibiting symptoms of lactose intolerance, such as more than about 2, 3, 4, 5, 10, 20, or 30 individuals.
- the decrease of symptoms of lactose intolerance persists or becomes even greater (e.g., 50% decrease to 55% decrease) for at least about 1 day, 1 week, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 9 months, one year, 18 months, two years, three years, four years, five years, or more than five years after the termination of treatment.
- the decrease in symptoms is permanent.
- the invention provides a method of decreasing symptoms of lactose intolerance in an individual exhibiting symptoms of lactose intolerance by administering to the individual increasing amounts of lactose for a period of time, wherein the symptoms of lactose intolerance, measured as described herein, are decreased by an average of about least about 20% and remain decreased by at least about 20% for at least about one month after treatment is terminated.
- the invention provides a method of decreasing symptoms of lactose intolerance in an individual exhibiting symptoms of lactose intolerance by administering to the individual increasing amounts of lactose for a period of time, wherein the symptoms of lactose intolerance, measured as described herein, are decreased by an average of about least about 50% and remain decreased by at least about 50% for at least about one month after treatment is terminated.
- the total duration of treatment may be from about two weeks to about 12 weeks, or about four weeks to about ten weeks, or about four weeks to about eight weeks, or about six weeks.
- the subject is started on a program of taking increasing amounts of the lactose containing product of the invention, optionally along with ingestion of lactose containing food products, and in some embodiments also in combination with other substances, as described herein.
- the total duration of treatment is about 15 days to about 90 days, or about 15 days to about 60 days, or about 20 days to about 50 days, or about 20 days to about 40 days, or about 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 days.
- the total duration of treatment is about 38 days.
- the total duration of treatment is about 42 days. It will be appreciated that these durations are averages, and that individuals using the treatment may vary from the average based on the severity of their symptoms, missing days of treatment, and the like. In some embodiments, the duration of the treatment is based on the individual's symptoms.
- an individual may experience a return of symptoms at a given dose of lactose, and may require that they stay at that dose, or a lower dose, until symptoms subside.
- the duration of the treatment is not definitively established at the outset, but continues until the highest dose of lactose is achieved, or until the desired level of lactose tolerance is achieved
- lactose is initially administered once per day, at increasing doses, followed by twice per day administration, also at increasing doses.
- the once per day administration can last for a period of about 6 to 30, or about 10 to 26, or about 14 to 22, or about 16 to 20, or about 18 days
- the twice per day administration can last for a period of about 4 to 28, or about 8 to 24, or about 12 to 20, or about 14 to 28, or about 16 days.
- the first dose of lactose is constant while the second dose increases.
- lactose may be administered an average of about once per day, twice per day, three, four, five, six, or more than six timer per day, or any combination thereof.
- the individual self-administers the lactose-containing product.
- the lactose-containing product is supplied or recommended by a health professional, e.g., a dietician, nutritionist, nurse, physician, or other qualified health professional.
- the lactose-containing product is administered by a health professional and/or results of the program are monitored by a health professional.
- the lactose-containing product is labeled as a medical food.
- an individual may have repeated courses of treatment.
- the course of treatment may be repeated when symptoms of lactose intolerance appear or increase to an undesirable level.
- the course of treatment may be repeated at regular or predetermined intervals.
- treatment may be repeated after about one month, two months, three months, four months, six months, eight months, ten months, one year, 18 months, two years, three years, four years, five years, or more than five years, or any combination thereof (e.g., treatment may be repeated after one year, then every two to five years thereafter).
- the treatment may be repeated in the same form (e.g., duration, dosage, timing of dosage, additional substances, etc.) as used in the first treatment, or it may be modified.
- treatment duration may be shortened or lengthened, dosage may be increased more quickly or slowly and/or a higher or lower starting dose of lactose may be used, a different lactose-containing product may be used (e.g., containing more or less of other substances, or fewer or more substances in addition to lactose), and the like.
- the starting dose of lactose and the incremental increases in lactose dosage may be any suitable dose size.
- the starting dose of lactose is about 0.05 to 4.0 gm, or about 0.1 to about 3 gm, or about 0.2 to about 3.0 gm, or about 0.2 to about 2 gm, or about 0.4 to about 1.6 gm, or about 0.4 to about 1.4 gm, or about 0.6 to about 1.2 gm, or about 0.6 to about 1.0 gm, or about 0.7 to about 0.9 gm, or about 0.8 gm.
- the incremental increase in lactose dosage can vary, or each increase can be the same, or any combination thereof.
- the lactose dosage may increase incrementally by about 0.05 to 4.0 gm, or about 0.1 to about 3 gm, or about 0.2 to about 3.0 gm, or about 0.2 to about 2 gm, or about 0.4 to about 1.6 gm, or about 0.4 to about 1.4 gm, or about 0.6 to about 1.2 gm, or about 0.6 to about 1.0 gm, or about 0.7 to about 0.9 gm, or about 0.8 gm.
- the maximum dose reached in treatment again may be any suitable dose size, depending on the individual being treated and the outcome desired.
- the maximum dose of lactose may be about 6 to about 60 gm, or about 12 to about 48 gm, or about 14 to about 36 gm, or about 16 to about 36 gm, or about 18 to about 34 gm, or about 20 to about 32 gm, or about 22 to about 30 gm, or about 23 to about 29 gm, or about 24 to about 28 gm, or about 25 to about 27 gm, or about 25.5 to about 26.5 gm, or about 25.5, 25.6, 25.7 gm.
- the initial dose of lactose is about 0.8 gm, and the dose is increased by 0.8 gm over time, for example, daily, until a maximum dose of 25.6 gm of lactose is reached.
- Additional phases of the regimen may include giving various amounts of milk products in which the dosage of lactose may be given in dairy form, before the treatment ends, and the dosage of lactose in the milk products may not be precisely the same as the doses given up to that point; it will be understood that various milk products and brands of milk products may contain varying doses of lactose.
- the lactose may be given in any suitable form, i.e., as a powder, such as in capsules or tablets, or powder that may be dissolved in a liquid prior to consumption, or in liquid form, e.g., predissolved in a liquid or in the form of milk. Any grade or form of lactose that is suitable for consumption by the individual being treated, e.g., by humans, may be used. Lactose-containing products useful in the invention are described more fully below.
- Additional substances may be given in conjunction with lactose. These substances can enhance the action of the increasing doses of lactose by, e.g., encouraging the growth of bacteria in the gut that alleviate symptoms of lactose intolerance, increasing adhesion of friendly bacteria, or allowing doses of friendly bacteria to more readily pass through the stomach without being destroyed. These substances may be given prior to treatment with lactose, during treatment with lactose, after treatment with lactose, or any combination thereof. If administered during lactose treatment, they may be administered with the dose of lactose being given, or before or after the dose of lactose, or any combination thereof.
- Substances of use in the invention in conjunction with lactose include live bacteria, fructooligosaccharides (FOS), and buffers, e.g., phosphates.
- FOS fructooligosaccharides
- buffers e.g., phosphates.
- lactose is administered in conjunction with live bacteria.
- lactose is administered in conjunction with FOS.
- lactose is administered in conjunction with buffer, e.g., phosphates.
- lactose is administered in conjunction with live bacteria and FOS. In some embodiments, during some or all of the treatment, lactose is administered in conjunction with live bacteria and phosphates. In some embodiments, during some or all of the treatment, lactose is administered in conjunction with FOS and buffer, e.g., phosphates. In some embodiments, during some or all of the treatment, lactose is administered in conjunction with live bacteria, FOS and buffer, e.g., phosphates
- Live bacteria e.g., live cultured bacteria
- any suitable bacteria for assisting in reduction or elimination of the symptoms of lactose intolerance typically such bacteria will be probiotic.
- Probiotic bacteria favorably alter the intestinal microflora balance, inhibit the growth of harmful bacteria, promote good digestion, boost immune function, and increase resistance to infection. People with flourishing intestinal colonies of beneficial bacteria are better equipped to fight the growth of disease-causing bacteria.
- Probiotic bacteria such as lactobacilli and bifidobacteria are thought to maintain a healthy balance of intestinal flora by producing organic compounds, such as lactic acid, hydrogen peroxide, and acetic acid, that increase the acidity of the intestine and inhibit the reproduction of many harmful bacteria.
- Probiotic bacteria also produce substances called bacteriocins, which act as natural antibiotics to kill undesirable microorganisms.
- Nonexclusive examples of probiotic bacteria that may be used in the methods of the invention include L. acidophilus or lactobacillus acidophilus. Acidophilus, a probiotic, is one of the most important strains of the Lactobacilli family of microflora which inhabit the gastrointestinal tract. These “good” bacteria are involved with immune system function, inhibiting carcinogenesis, metabolism of cholesterol, aging, and nutritional status. Acidophilus and other probiotic bacteria help maintain optimum pH, reduce putrefaction, and reduce endotoxemia.
- lactobacillus bacteria which may be employed include Lactobacillus crispatus, Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus reuteri, Lactobacillus fermentum, L. plantarum, L. sporogenes, L. bulgaricus and Lactobacillus rhamnosus .
- Other probiotic bacteria include Bifidobacterium lactis, B. bifidum, B. infantis, Saccharomyces boulardii .
- the bacteria may be given as part of a food, e.g., in yoghurt, or in powdered form. Mixtures of one or more species or strains of bacteria may be used.
- probiotic bacteria such as L. acidophilus
- probiotic bacteria is given prior to beginning treatment with lactose.
- probiotic bacteria such as L. acidophilus
- probiotic bacteria is given in conjunction with treatment with lactose, for part or all of the treatment with lactose.
- some or all doses of lactose are accompanied by a dose of bacteria, e.g. live cultured bacteria, e.g., L. acidophilus .
- bacteria, e.g., L. acidophilus is given initially with the lactose, but then its use is discontinued.
- the initial one, two, three, four, five, six, seven, eight, nine, ten, or more than ten days of treatment with lactose may include doses of bacteria, with the use of bacteria discontinued after that time.
- bacteria e.g. bacteria in yoghurt, or bacteria by themselves, may be given for the first two days of treatment, then the administration of bacteria is discontinued.
- probiotic bacteria either alone or in combination with other substances or treatments are used after the treatment with lactose is terminated.
- the bacteria may be taken for any suitable period after the termination of treatment with lactose, and may be taken daily or at regular or irregular intervals. Doses may be as described below.
- bacteria are given as live cultured bacteria, e.g., in combination with lactose and, optionally, other substances.
- the dose can be about 1 to about 1000 mg, or about 2 to about 200 mg, or about 2 to about 100 mg, or about 2 to about 50 mg, or about 4 to about 25 mg, or about 5 to about 20 mg, or about 10 to about 15 mg, or about 10, 11, 12, 12.5, 13, 14, or 15 mg.
- L. acidophilus is used in a dose of about 12.5 mg.
- the dose may be given in combination with lactose. In some embodiments, as lactose dose increases, the dose of bacteria increases as well.
- an initial dose of lactose may be about 0.6 to 1.0 gm, e.g., 0.8 gm, given in combination with about 10-15 mg, e.g., about 12.5 mg, of L. acidophilus .
- the dose of lactose may be increased incrementally by about 0.6 to 1.0 gm, e.g., 0.8 gm, and the accompanying dose of L. acidophilus may be increased by about 10-15 mg, e.g., about 12.5 mg, of L. acidophilus.
- Fructooligosacharides are a non-digestible, soluble-fiber that supports the growth of beneficial bacteria in the intestinal tract, particularly two important strains—1. acidophilus and 1. bifidus. These two strains play an essential role in reducing the number of pathogenic bacteria. Additional nutritional properties, such as the effect on colonic pH and stool bulking justify their classification as dietary fibers. In experimental models, it has also been reported that they improve the bioavailability of essential minerals. As a fiber, it is thought to slow digestion and allow the painless reintroduction of lactose into the body.
- FOS are chain polymers of the sugar fructose that are found in a variety of foods.
- the sugar units can be linked in a single straight chain or can be a chain with side branches. In many cases small amounts of glucose are also contained in the chain.
- the length of the fructose chains can vary from source to source. Inulin is an example of a longer chained compound that is considered a FOS. The shorter (lower molecular weight) compounds tend to have a sweet taste.
- the size and complexity of the FOS molecule gives it desirable characteristics. Although the simple sugars fructose and glucose are quickly absorbed into the body by the intestines, FOS for the most part is indigestible and therefore acts as a non-digestible fiber in the diet. This is because the human does not have the enzymes to break down the FOS as it travels down the digestive tract.
- FOS are given prior to beginning treatment with lactose.
- FOS are given in conjunction with treatment with lactose, for part or all of the treatment with lactose.
- some or all doses of lactose are accompanied by a dose of FOS.
- FOS are given initially with the lactose, but then their use is discontinued.
- the initial one, two, three, four, five, six, seven, eight, nine, ten, or more than ten days of treatment with lactose may include doses of FOS, with the use of FOS discontinued after that time.
- FOS may be given for the first two days of treatment, then the administration of FOS is discontinued.
- FOS either alone or in combination with other substances or treatments are used after the treatment with lactose is terminated.
- the FOS may be taken for any suitable period after the termination of treatment with lactose, and may be taken daily or at regular or irregular intervals. Doses may be as described below.
- FOS may be used in a dose from about 1 mg to about 10 gm, or about 1 mg to about 5 gm, or about 2 mg to about 1000 mg, or about 2 mg to about 500 mg, or about 2 mg to about 200 mg, or about 2 mg to about 100 mg, or about 2 mg to about 50 mg, or about 2 mg to about 20 mg, or about 5 mg to about 10 mg, or about 5, 6, 7, 7.5, 8, 9, or 10 mg.
- FOS are used in a dose of about 7.5 mg.
- the dose may be given in combination with lactose.
- an initial dose of lactose may be about 0.6 to 1.0 gm, e.g., 0.8 gm, given in combination with about 5-10 mg, e.g., about 7.5 mg, of FOS.
- the dose of lactose may be increased incrementally by about 0.6 to 1.0 gm, e.g., 0.8 gm, and the accompanying dose of FOS may be increased by about 5-10 mg, e.g., about 7.5 mg, of FOS.
- One or more buffers may also be administered in methods of the invention.
- Any buffer suitable for consumption by the individual being treated e.g., human, may be used.
- the buffer neutralizes stomach acidity which can, e.g., allow live bacteria to reach the gut.
- Buffers include citrates, phosphates, and the like.
- Some embodiments of the invention utilize a buffer with a calcium counterion, such as Calcium Phosphate Tribasic.
- the calcium can serve to restore the calcium that many lactose intolerant individuals are missing in their diet.
- a recent study demonstrated the ability of calcium phosphate to protect lactobacillus acidophilus from bile. It is an excellent buffering agent and will help neutralize stomach acidity.
- a buffer such as calcium phosphate is given prior to beginning treatment with lactose, e.g., in conjunction with administration of bacteria.
- a buffer such as calcium phosphate is given in conjunction with treatment with lactose, for part or all of the treatment with lactose.
- some or all doses of lactose are accompanied by a dose of a buffer such as calcium phosphate.
- a buffer such as calcium phosphate is given initially with the lactose, but then its use is discontinued.
- the initial one, two, three, four, five, six, seven, eight, nine, ten, or more than ten days of treatment with lactose may include doses of a buffer such as calcium phosphate, with the use of the discontinued after that time.
- a buffer such as calcium phosphate may be given for the first two days of treatment, then the administration of buffer is discontinued.
- a buffer such as calcium phosphate either alone or in combination with other substances or treatments is used after the treatment with lactose is terminated.
- the a buffer such as calcium phosphate may be taken for any suitable period after the termination of treatment with lactose, and may be taken daily or at regular or irregular intervals. Doses may be as described below.
- the buffer may be used in a dose from about 2 to about 2000 mg, or about 4 to about 400 mg, or about 4 to about 200 mg, or about 4 to about 100 mg, or about 8 to about 50 mg, or about 10 to about 40 mg, or about 20 to about 30 mg, or about 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 mg. In some embodiments, buffer is used in a dose of about 25 mg.
- calcium phosphate is used in a dose of about 25 mg.
- the dose may be given in combination with lactose.
- the dose of buffer increases as well.
- an initial dose of lactose may be about 0.6 to 1.0 gm, e.g., 0.8 gm, given in combination with about 20-30 mg, e.g., about 25 mg, of buffer, e.g., calcium phosphate.
- the dose of lactose may be increased incrementally by about 0.6 to 1.0 gm, e.g., 0.8 gm, and the accompanying dose of buffer, e.g., calcium phosphate, may be increased by about 20-30 mg, e.g., about 25 mg, of buffer, e.g., calcium phosphate.
- buffer e.g., calcium phosphate
- treatment with lactose is used in combination with other treatments to reduce the symptoms of lactose intolerance.
- Any suitable treatment for the reduction of symptoms of lactose intolerance may be used, e.g., the use of lactase.
- Lactase may be administered before, during, or after treatment with lactose, or any combination thereof.
- lactase is administered after lactose treatment is terminated. The lactase may be used on an as-needed basis.
- the treatment occurs in phases.
- One phase utilizes a single administration of lactose per day, generally though not necessarily with food, e.g., dinner.
- the dose of lactose increases over time.
- the dose of lactose may increase each day.
- Another phase generally following the first phase, utilizes two administrations of lactose per day, again, generally with food, e.g., with breakfast and dinner. Again, during this phase the dose of lactose increases over time, e.g., increasing each day.
- the invention includes one phase in which lactose is administered once per day in conjunction with live bacteria. This phase, if used, is generally the first phase of the method.
- live bacteria may be administered during some or all of the entire period of treatment.
- live bacteria are included in a lactose-containing product that is administered to the individual.
- lactose-containing product typically, during the preceding phases no dairy products are consumed.
- a final phase of the protocol can involve the gradual reintroduction of dairy into the diet, either with or without the continuing use of the lactose-containing product used in the first phases of treatment. Finally, treatment is concluded and no further ingestion of lactose-containing product is required.
- the lactose containing products administration for two days, along with live bacteria, e.g., yoghurt containing live cultures.
- the lactose containing product is taken with food and typically a dinner for a period of about 10 to 30, or about 14 to 24, or about 16 to 20, or about 18 days.
- the lactose containing product is taken with both dinner and breakfast for another period of about 6 to 18, or about 8 to 16, or about 10 to 14, or about 12 days.
- the lactose containing product is administered with both dinner and breakfast, along with the addition of other diary products.
- diary products are not consumed during the first phases, e.g., the first about 34 days of the regimen.
- This total period e.g., of approximately 38 days, constitutes the full period in which the lactose containing product is consumed, but more importantly consumed essentially in these time periods.
- the regimen includes the actual ingestion of diary products for about at least every few days to maintain and build up the complete tolerance, but without the administration of the lactose containing product.
- the amount of the lactose containing product administered at dinner time increases regularly each day.
- the amount of the lactose containing product increases regularly each day in combination with a breakfast meal.
- a lactose containing food item such as milk, also is regularly increased for those 4 days.
- a first dose of the lactose containing product is administered in increasing amounts for a 6-week period.
- probiotic bacteria e.g., in a food containing product also having a live culture bacteria is administered with the lactose containing product.
- a food item containing a live cultured bacteria is yoghurt.
- a second dose of the lactose containing product is administered, typically at breakfast time.
- An example of the dosing regimen is shown in the following table:
- the subject In the first day of the regimen, the subject ingests 8 ounces of yoghurt or other food product containing a live culture bacteria, along with 1 tablespoon of milk, at the dinner meal. As an example and considering the regimen shown in Table I, the subject will ingest 8 ounces of live culture bacterial yoghurt on the first day, along with 1 tablespoon of milk with dinner. On the second day, the amount of the yoghurt ingested is reduced to 4 ounces, although the administration of the milk remains the same. On the third day, administration of the yoghurt is ceased, but the milk remains at 1 tablespoon. During the fourth through the 18th days, the amount of milk ingested with dinner is increased by 1 tablespoon each day until 16 tablespoons are reached on the day 18.
- Table I is only a single exemplary 6-week regimen.
- the actual days can vary, and the quantity of the dosages can similarly be modified according to each particular subject and the reactions encountered by that subject. Even though there may be variations in both the time period and the dosage rates, the concept of increasing the dosages of the lactose containing product for specific time periods is maintained and encompassed by the present invention.
- the subject is capable of ingesting more than 5 tablespoons of milk by day 7. As a result, the amount of milk ingested by day 7 may be increased to 6 tablespoons, etc. Determination of whether or not the subject is capable of increasing the dosage or the time period depends on whether or not the subject encounters any adverse affects. In the event that the subject does encounter adverse affects, the subject should resort back to the regimen as specified in Table I.
- the same alterations can be made in the time intervals between the administration of the lactose containing product and the various other lactose containing food items.
- the subject could potentially alter the amount of the lactose food item every 12 hours.
- that time period could vary to 36 or even 48 hours:
- the lactose containing product of the invention may be administered as a pure powder lactose, the latter of which is mixed with water and consumed much in the same manner as a soft drink.
- the amount of the lactose can also be incorporated in one or more capsules, or otherwise, in the loose granular form, as indicated.
- the designation “s” refers to a single zero sized capsule containing 0.8 gm of pure lactose powder, and this is equivalent to about 1 tablespoon of milk.
- the designation “m” refers to a double-sized zero capsule, which may be filled with 1.6 grams of lactose powder.
- the amount of the lactose ingested in any time interval, in accordance with Table II, is substantially identical to that regimen as shown in Table I. However, the form of the lactose is different.
- lactose need not be administered with bacteria.
- the standard protocol starts with a subject taking 0.8 grams of lactose with a dinner.
- the subject increases the dosage of lactose by 0.8 grams, thus they go from having 0.8 grams on day 1, to 1.6 grams on day 2, and 2.4 grams on day 3.
- the subject starts the same process with breakfast, by taking 0.8 grams on day 17, then 1.6 grams on day 18 and so on. While this is going on, the subject continually takes 12.8 grams of lactose with dinner.
- the subject starts to re-introduce dairy products into their daily diet. While the dairy foods may vary, milk is the standard product a subject starts out with.
- the subject Starting with drinking 6 ounces with breakfast and dinner, the subject gradually drinks 8 ounces, 10 ounces and 12 ounces of milk per day. At day 36, the subject has completed the protocol and may now enjoy dairy products pain-free. No future protocol, supplements or medication is needed for these subjects to consume dairy products.
- the doses shown here have been used and tested, variations in the doses and timing in which they are administered can still result in an effective treatment for increasing tolerance for lactose containing product.
- the presented doses have been tested on adult subjects.
- the weight of the subject might be a consideration.
- a subject weighing 50 pounds may not require, and may not be capable of tolerating, the doses set forth in Table 1 at prescribed time in the protocol.
- the dose administered to the subject may be proportionally scaled down based on his weight.
- the doses are disclosed as being administered with breakfast and dinner, alternatively the order of the doses may be switched, or may be administered at other times of the day with meals such as lunch or snacks (or conceivably with no meals).
- the program may also be reduced into a shortened or lengthened program.
- the program can work with an abbreviated 4 week program or it can be lengthened up to a 10 week program.
- the invention has been described for use in humans, it is also capable of being administered to other mammals.
- the invention also provides compositions for the treatment of the symptoms of lactose intolerance.
- the compositions contain lactose and one or more of: bacteria, FOS, and/or buffer. Additional ingredients include ingredients to improve handling, preservatives, flavorings and the like.
- the composition contains lactose and bacteria.
- the lactose will typically comprise more than 50% of the weight of the composition while the bacteria will typically comprise less than about 10%, 5%, 4%, 3%, or 2% of the compositions (all percentages are weight percent unless otherwise indicated).
- lactose may be present at about 80-99.75% and the bacteria at about 0.25-2.10%, or the lactose may be present at about 89-94% and the bacteria at about 1.2-3.75%.
- lactose is present at about 94.01% and bacteria, e.g., L. acidophilus , is present at about 1.47%.
- the remaining ingredients may be any suitable ingredients intended for the consumption of the individual, e.g., human, including, but not limited to, FOS and/or buffer, but also including ingredients intended to inhibit clumping and increase pourability, such as silicone dioxide and microcrystalline cellulose, or similar ingredients as are well-known in the art.
- the compositions contain lactose and FOS.
- lactose may be present at about 80-99.75% and the FOS at about 0.10-1.89%, or the lactose may be present at about 89-94% and the FOS at about 0.40 to about 1.26%. In some embodiments, lactose is present at about 94.01% and FOS is present at about 0.88%.
- the remaining ingredients may be any suitable ingredients intended for the consumption of the individual, e.g., human, including, but not limited to, bacteria and/or buffer, but also including ingredients intended to inhibit clumping and increase pourability, such as silicone dioxide and microcrystalline cellulose, or similar ingredients as are well-known in the art.
- the compositions contain lactose and buffer, e.g., calcium phosphate tribasic.
- lactose may be present at about 80-99.75% and the buffer at about 0.50-4%, or the lactose may be present at about 89-94% and the buffer at about 1.2 to about 3.75%. In some embodiments, lactose is present at about 94.01% and buffer is present at about 2.94%.
- the remaining ingredients may be any suitable ingredients intended for the consumption of the individual, e.g., human, including, but not limited to, bacteria and/or FOS, but also including ingredients intended to inhibit clumping and increase pourability, such as silicone dioxide and microcrystalline cellulose, or similar ingredients as are well-known in the art.
- the compositions contain lactose, bacteria (e.g., L. acidophilus ), and FOS.
- lactose may be present at about 80-99.75%, bacteria at about 0.25-2.10%, and the FOS at about 0.10-1.89%, or the lactose may be present at about 89-94%, bacteria at about 0.91-1.95% and the FOS at about 0.40 to about 1.26%.
- lactose is present at about 94.01%, bacteria at about 1.47%, and FOS is present at about 0.88%.
- the remaining ingredients may be any suitable ingredients intended for the consumption of the individual, e.g., human, including, but not limited to buffer, but also including ingredients intended to inhibit clumping and increase pourability, such as silicone dioxide and microcrystalline cellulose, or similar ingredients as are well-known in the art.
- the compositions contain lactose, bacteria, and buffer.
- lactose may be present at about 80-99.75%, bacteria at about 0.25-2.10%, and the buffer at about 0.50-4%, or the lactose may be present at about 89-94%, bacteria at about 0.91-1.95% and the buffer at about 1.2 to about 3.75%.
- lactose is present at about 94.01%, bacteria at about 1.47%, and buffer is present at about 2.94%.
- the remaining ingredients may be any suitable ingredients intended for the consumption of the individual, e.g., human, including, but not limited to, FOS, but also including ingredients intended to inhibit clumping and increase pourability, such as silicone dioxide and microcrystalline cellulose, or similar ingredients as are well-known in the art.
- the compositions contain lactose, FOS, and buffer.
- lactose may be present at about 80-99.75%, FOS at about 0.10 to about 1.89%, and the buffer at about 0.50-4%, or the lactose may be present at about 89-94%, FOS at about 0.40 to about 1.26%, and the buffer at about 1.2 to about 3.75%.
- lactose is present at about 94.01%, FOS at about 0.88%, and buffer is present at about 2.94%.
- the remaining ingredients may be any suitable ingredients intended for the consumption of the individual, e.g., human, including, but not limited to, bacteria, but also including ingredients intended to inhibit clumping and increase pourability, such as silicone dioxide and microcrystalline cellulose, or similar ingredients as are well-known in the art.
- the compositions contain lactose, bacteria, FOS, and buffer.
- lactose may be present at about 80-99.75%, bacteria at about 0.25 to about 2.10%, FOS at about 0.10 to about 1.89%, and the buffer at about 0.50-4%, or the lactose may be present at about 89-94%, bacteria at about 0.91 to about 1.95%, FOS at about 0.40 to about 1.26%, and the buffer at about 1.2 to about 3.75%.
- lactose is present at about 94.01%, bacteria at about 1.47%, FOS at about 0.88%, and buffer is present at about 2.94%.
- the remaining ingredients may be any suitable ingredients intended for the consumption of the individual, e.g., human, including, but not limited to, ingredients intended to inhibit clumping and increase pourability, such as silicone dioxide and microcrystalline cellulose, or similar ingredients as are well-known in the art.
- compositions include microcrystalline cellulose and silicone dioxide.
- weights are merely exemplary, and may be varied.
- the weight of lactose is 800 mg (0.8 g) and the other weights may be adjusted accordingly:
- compositions of the invention include any suitable form, including liquid or powder.
- Powdered compositions may be as pure powder, or may be in the form of capsules, tablets, or the like.
- Powder may be packaged in bulk (e.g., in a container containing sufficient lactose and/or other substances for one individual to follow an entire course of treatment with increasing doses of lactose, or a portion of a course of treatment), or as individual packets (e.g., packets containing a single dose of lactose plus other components, or packets containing the dose of lactose and other components needed for a particular day of a lactose treatment regimen). If packaged in bulk, the powder may be in any suitable container.
- the container may also include one or more scoops or similar serving devices of a size or sizes appropriate to measure and serve one or more doses of lactose and, optionally, other ingredients included in the powder.
- Liquid compositions contain lactose and, optionally, other ingredients, in a suitable liquid, e.g., water or buffer.
- Liquid compositions may be provided in bulk (e.g., in a container containing sufficient lactose and/or other substances for one individual to follow an entire course of treatment with increasing doses of lactose, or a portion of a course of treatment), or as individual containers, such as cans, bottles, soft packs, and the like (e.g., containers containing a single dose of lactose plus other components in suitable liquid, or containers containing the dose of lactose and other components needed for a particular day of a lactose treatment regimen).
- the container may also include one or more measuring cups or similar serving devices of a size or sizes appropriate to measure and serve one or more doses of lactose and, optionally, other ingredients included in the liquid.
- kits for the treatment of the symptoms of lactose intolerance include lactose in suitable packaging for use by an individual in the treatment of symptoms of lactose intolerance. Any of the compositions described herein may be packaged in the form of a kit.
- a kit may contain an amount of lactose and, optionally, other ingredients as described herein, sufficient for an entire course of treatment, or for a portion of a course of treatment.
- a kit may include sufficient lactose for the first, second, third, fourth, fifth, and sixth weeks of treatment, or additional weeks of treatment if used, or any combination thereof.
- kits provide, in suitable packaging, individual doses of lactose that correspond to dosing points in a treatment regimen, wherein the doses are packaged in one or more packages intended for use in the treatment of symptoms of lactose intolerance.
- a kit may contain doses of lactose, as described herein, for a treatment program, where the lactose is taken in increasing doses, so that individual packets of lactose are increasing in amount of lactose contained in the packet, from lower doses intended for use at the start of the program to higher doses as the program progresses.
- each packet may be labeled to indicate the day and time of day that it is intended to be taken, or the packaging containing the packets may be so labeled, or both.
- a “packet,” as used in this context, is any individual container that contains lactose, whether the lactose is in solid or liquid form, and can include a packet that contains powder, tablets, or pills, or a packet that contains a liquid.
- the lactose may be provided in bulk in a single container, or in two, three, four, five, or more than five containers (e.g., where each container contains enough lactose for a particular week of a treatment program). If more than one bulk container is provided, the bulk containers may be suitably packaged together to provide sufficient lactose for all or a portion of a treatment protocol.
- the container or containers can be labeled with a label indicating information useful to the individual performing the treatment protocol, such as dosing schedules.
- kits of the invention include a powder or liquid containing all the ingredients intended to be used in a course of treatment or a portion of a course of treatment, e.g., lactose and bacteria, FOS, and/or buffer.
- lactose is packaged in one package or set of packages, and additional components, such as bacteria, FOS, and/or buffer, are packaged separately from the lactose.
- Kits may further include written materials, such as instructions, expected results, testimonials, explanations, warnings, clinical data, information for health professionals, and the like.
- the kits contain a label or other information indicating that the kit is only for use under the direction of a health professional, such as a dietician, nutritionist, nurse, physician, or other appropriate health professional.
- the kits contain or include information, such as a label, designating the material within as a medical food.
- the invention provides a kit that includes a container of powder, where the powder includes lactose, and additionally FOS, bacteria, and/or buffer, and a label on the container that indicates proper dosage and schedule of use for the powder.
- the container may further include scoops or other measuring and/or serving devices.
- the invention provides a kit that includes a container of liquid, where the liquid includes lactose, and additionally FOS, bacteria, and/or buffer, and a label on the container that indicates proper dosage and schedule of use for the liquid.
- the container may further include measuring and/or serving devices.
- the invention also provides business methods for marketing compositions and methods for the treatment of the symptoms of lactose intolerance.
- the invention provides a method of doing business that includes marketing a composition for the treatment of symptoms of lactose intolerance wherein the treatment is by administering increasing doses of lactose according to any of the methods described herein, optionally in combination with other substances such as FOS, bacteria, and buffers
- the composition is part of a kit, as described herein.
- the methods may further include producing such compositions or kits.
- the marketing may be directly to the consumer, or to suitable health professionals, or combinations thereof.
- the methods of marketing used in these embodiments of the invention include, but are not limited to, print, television, or radio commercials, infomercials, internet advertising, testimonials, word of mouth, telemarketing, and the like.
- the standard regimen starts with each subject of a group taking 0.8 grams of lactose with dinner each evening. On days 2-16, the dosage of the lactose is increased by 0.8 grams, such that on day 2, the subject takes 1.6 grams, and on day 3, takes 2.4 grams. This process continues until day 16. On day 17, the subject starts the same process with breakfast by consuming 0.8 grams of the product on day 17 and 1.6 grams on day 18. This process continues elevating at the same rate. Simultaneously therewith, the subject is taking 12.8 grams of the lactose-containing product with dinner.
- each subject starts a reintroduction of diary products into their daily diet. While the diary products may vary, milk is typically the standard product, at least as a starting point. When milk is used, the subject starts with 6 ounces with breakfast and dinner, and gradually increases to 8 ounces, 10 ounces, 12 ounces of milk per day. On day 36, the subject has completed the entire regimen and is able to consume dairy products thereafter with decreased lactose intolerant symptoms. An example of this dosing regimen is shown below in the Table.
- the doses can be varied in the actual times of application.
- the regimen can be used with the subject starting out at a breakfast time and increasing the dosages on the 17th day at dinner time.
- other times of the day could be used.
- the quantities can vary, depending on the physical conditions of the user.
- dosages can be reduced.
- a double-blind study of the ability of the lactose-based compositions and methods of the invention was made in order to determine reduction of the symptoms of lactose intolerance. More specifically, the study was conducted to determine whether graduated and controlled administration of lactose-containing product of the invention to subjects who have been confirmed as having lactose intolerance was effective in order to determine if the regimen of the invention was effective in relieving their lactose intolerant symptoms. For this purpose, a double-blind randomized study was conducted with the subjects following the 38-day regimen with a placebo, or otherwise, the lactose-containing product, itself.
- each of the subjects were paired by age group and gender. Most members of each pair of subjects began the program within two days. One member of the pair randomly received a supply of the lactose-containing product, while the other received a placebo. This placebo was similar in appearance to the actual lactose-containing product. Detailed instructions for administration were given to each participant. In short, each subject was instructed to take the powdered formula, as well as the powdered placebo, and mix same with water for ingestion. Particular preparation dispensed to each subject was unknown both to the subject and the dispensing individual. A record of each was kept by a third party.
- Example 1 In conducting the study, the regimen described in Example 1 was used. Also, the lactose-containing product of the Table IV of ingredients in the Compositions section, above, was used and particularly that product identified as having the exemplary percentages.
- Each subject was contacted once a week for the first two weeks, and then each week thereafter, in order to check on their progress. Directions were provided on a personal basis if changes were needed. During the entire program, 5 extra days were included, and each subject was asked to follow this 42-day program until completion. On days 35-37, each subject consumed a measured amount of milk with breakfast and dinner. On day 38, the subjects were asked to incorporate at least 16 ounces of diary product into their diet for the next 5 days. Upon completion, each subject again rated their symptoms using the same Likert scale which was used in the pre-screening procedure. Subjects were again asked for another rating of symptoms after one month of completion of the program.
- the data collected from the symptom score sheets was analyzed. Participants provided ratings for five symptoms of lactose intolerance on a 0 (no symptom) to 4 (severe symptom) sale. Data collection was successful. The total symptom scale provided scores ranging from 0 to 20. Data were collected pre-treatment for 73 individuals and 64 individuals (87.7%) completed the program and provided data at the conclusion of that program. Completion rates were 88.9% for those assigned to the group receiving the lactose product and 86.9% for those assigned to the placebo group. 61 individuals provided data between one and two months following completion of the program.
- the group receiving the lactose-containing product provided symptom ratings that, in total, were 54.1 percent lower than their original ratings, while the placebo group ratings declined by only 26.3 percent.
- the present study confirmed the occurrence of decrease of symptoms when lactose intolerant subjects ingested a formulated lactose-containing product for 38 days and showed a decrease in the severity of all symptoms when they were challenged with a lactose load (8, 10, and 12 oz glass of milk) after metabolic adaptation compared with pre-adaption severity. Post one month data demonstrated the same degree of improved symptoms as subjects continued to incorporate dairy products into their diets.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Business, Economics & Management (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Development Economics (AREA)
- Finance (AREA)
- Strategic Management (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Accounting & Taxation (AREA)
- Theoretical Computer Science (AREA)
- Physics & Mathematics (AREA)
- Entrepreneurship & Innovation (AREA)
- General Physics & Mathematics (AREA)
- Game Theory and Decision Science (AREA)
- General Business, Economics & Management (AREA)
- Economics (AREA)
- Marketing (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/632,289 US20080126195A1 (en) | 2004-07-22 | 2005-07-22 | Methods and Compositions for Treating Lactose Intolerance |
US12/055,936 US9226933B2 (en) | 2004-07-22 | 2008-03-26 | Methods and compositions for treating lactose intolerance |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71058804A | 2004-07-22 | 2004-07-22 | |
US10710588 | 2004-07-22 | ||
PCT/US2005/026095 WO2006012536A2 (fr) | 2004-07-22 | 2005-07-22 | Procedes et compositions pour le traitement de l'intolerance au lactose |
US11/632,289 US20080126195A1 (en) | 2004-07-22 | 2005-07-22 | Methods and Compositions for Treating Lactose Intolerance |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US71058804A Continuation-In-Part | 2004-07-22 | 2004-07-22 | |
CTPCT/CT2005/026095 A-371-Of-International | 2005-07-22 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/055,936 Continuation US9226933B2 (en) | 2004-07-22 | 2008-03-26 | Methods and compositions for treating lactose intolerance |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080126195A1 true US20080126195A1 (en) | 2008-05-29 |
Family
ID=35786731
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/632,289 Abandoned US20080126195A1 (en) | 2004-07-22 | 2005-07-22 | Methods and Compositions for Treating Lactose Intolerance |
US12/055,936 Expired - Fee Related US9226933B2 (en) | 2004-07-22 | 2008-03-26 | Methods and compositions for treating lactose intolerance |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/055,936 Expired - Fee Related US9226933B2 (en) | 2004-07-22 | 2008-03-26 | Methods and compositions for treating lactose intolerance |
Country Status (2)
Country | Link |
---|---|
US (2) | US20080126195A1 (fr) |
WO (1) | WO2006012536A2 (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080112941A1 (en) * | 1998-07-07 | 2008-05-15 | Ritter Andrew J | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
US20080233092A1 (en) * | 2004-07-22 | 2008-09-25 | Ritter Andrew J | Methods and compositions for treating lactose intolerance |
US20110189148A1 (en) * | 2008-06-25 | 2011-08-04 | Ritter Pharmaceuticals, Inc. | Lactose compositions with decreased lactose content |
US20110223248A1 (en) * | 2007-12-12 | 2011-09-15 | Ritter Pharmaceuticals, Inc. | Methods and compositions for treating lactose intolerance |
US20110236480A1 (en) * | 2009-02-24 | 2011-09-29 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
US8492124B2 (en) | 2009-02-24 | 2013-07-23 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
US20150328267A1 (en) * | 2010-02-05 | 2015-11-19 | Daniel Henry Wyrobnik | Composition for use in the therapy of lactose intolerance or conditions arising from lactase deficiency |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109757731A (zh) * | 2019-03-14 | 2019-05-17 | 广州普维君健药业有限公司 | 缓解乳糖不耐的益生菌组合物及其制备方法和应用 |
Citations (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3627583A (en) * | 1969-04-29 | 1971-12-14 | Sucrest Corp | Direct compression vehicles |
US4629694A (en) * | 1983-07-12 | 1986-12-16 | Cornell Research Foundation, Inc. | Detecting and distinguishing between plasminogen activators |
US4656066A (en) * | 1982-12-20 | 1987-04-07 | Warner-Lambert Company | Apparatus and method for sealing capsules |
US4806368A (en) * | 1987-09-16 | 1989-02-21 | Reddy Malireddy S | Shelf life and subsequent growth of lactobacillus acidophilus, propionibacterium shermanii and leuconostoc citrovorum in dietary fiber based supplement preparation |
US4888171A (en) * | 1984-04-18 | 1989-12-19 | Morinaga Milk Industry Co., Ltd. | Granular product of dried microorganism cells and manufacturing method therefor |
US4959234A (en) * | 1988-11-17 | 1990-09-25 | Electric Power Research Institute | Method for improving the taste, texture and mouth feel of a liquid dairy product and for concentrating same |
US4987150A (en) * | 1987-06-26 | 1991-01-22 | Kabushiki Kaisha Vitamin Kenkyusho | Agent for inhibiting binding of 5-dihydro-testosterone with androgen receptor as well as process for obtaining same |
US5219842A (en) * | 1989-08-29 | 1993-06-15 | Nihon Shokuhin Kako Co., Ltd. | Method of improving intestinal floras |
US5550106A (en) * | 1994-03-04 | 1996-08-27 | Bristol-Myers Squibb Company | Low buffer nutritional composition |
US5709857A (en) * | 1994-05-26 | 1998-01-20 | Dibra S.P.A. | Lactobacillus strains of human origin, their compositons and uses thereof |
US5716615A (en) * | 1992-02-10 | 1998-02-10 | Renata Maria Anna Cavaliere Vesely | Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use |
US5744134A (en) * | 1994-10-28 | 1998-04-28 | Metagenics, Inc. | Immunoglobulin and fiber-containing composition for human gastrointestinal health |
US5852021A (en) * | 1995-03-28 | 1998-12-22 | Ferrer Internacional, S.A. | Polymorph B of 1-(diphenylmethyl)-4- 3-(2-phenyl-1,3-dioxolan-2-YL) propyl! piperazine |
US5895648A (en) * | 1996-12-23 | 1999-04-20 | Sitia-Yomo S.P.A. | Composition for feed use comprising lyophilized live lactic bacteria |
US5952021A (en) * | 1994-06-14 | 1999-09-14 | Recordati S.A. Chemical And Pharmaceutical Company | Stabilized biologically active compounds contained in coated microgranules which can be suspended in alimentary fluids |
US5952205A (en) * | 1998-02-06 | 1999-09-14 | Neose Technologies, Inc. | Process for processing sucrose into glucose and fructose |
US6093425A (en) * | 1997-11-21 | 2000-07-25 | Princeton Nutrition, L.L.C. | Complete nutritional milk compositions and products |
US6221350B1 (en) * | 1996-03-20 | 2001-04-24 | The University Of New South Wales | Enhancement of microbial colonisation of the gastrointestinal tract |
US6241983B1 (en) * | 1994-10-28 | 2001-06-05 | Metagenics, Inc. | Bacteria-and fiber-containing composition for human gastrointestinal health |
US20020034496A1 (en) * | 1998-07-07 | 2002-03-21 | Andrew J. Ritter | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
US6368641B1 (en) * | 2000-04-28 | 2002-04-09 | Hartz International Inc. | Lactic acid bacteria and food products |
US6423833B1 (en) * | 1998-05-05 | 2002-07-23 | Steven J. Catani | Functional sugar polymers from inexpensive sugar sources and apparatus for preparing same |
US6468525B1 (en) * | 1999-08-10 | 2002-10-22 | Renew Life, Inc. | Probiotic formulation |
US6471999B2 (en) * | 1998-09-08 | 2002-10-29 | Nestec S.A. | Milk-based powder for pets |
US20030147995A1 (en) * | 2001-08-31 | 2003-08-07 | Ronald Koss | Nutritional frozen dessert and methods of manufacture |
US6706287B2 (en) * | 2001-05-15 | 2004-03-16 | Kibow Biotech Inc. | Prebiotic and probiotic compositions and methods for their use in gut-based therapies |
US20040057943A1 (en) * | 2002-06-28 | 2004-03-25 | Jordi Xaus Pey | Probiotic strains, a process for the selection of them, compositions thereof, and their use |
US20040161422A1 (en) * | 1999-04-30 | 2004-08-19 | Natarajan Ranganathan | Nutritional compositions comprising probiotics |
US6797266B2 (en) * | 2000-12-18 | 2004-09-28 | Probiohealth | Probiotic composition containing Lactobacillus casei strain ATCC PTA-3945 |
US6835376B1 (en) * | 1999-03-11 | 2004-12-28 | Nestec S.A. | Lactobacillus paracasei strain for preventing diarrhea caused by pathogenic bacteria |
US20050074442A1 (en) * | 2002-03-13 | 2005-04-07 | Natarajan Ranganathan | Compositions and methods for augmenting kidney function |
US20050079244A1 (en) * | 2001-11-12 | 2005-04-14 | Giffard Catriona Julie | Foodstuff |
US6929793B2 (en) * | 2000-11-14 | 2005-08-16 | Nestec S.A. | Nutritional composition for treating an immune condition |
US20050180962A1 (en) * | 2003-01-30 | 2005-08-18 | Eyal Raz | Inactivated probiotic bacteria and methods of use thereof |
US6960341B2 (en) * | 2002-09-06 | 2005-11-01 | Alfa Wassermann S.P.A. | Bifidobacteria and preparations containing them |
US20060093592A1 (en) * | 2004-10-04 | 2006-05-04 | Nutracea | Synbiotics |
US20060141097A1 (en) * | 2002-10-22 | 2006-06-29 | Mingruo Guo | Symbiotic food products comprising oats and methods for manufacturing the same |
US20060165670A1 (en) * | 2003-04-08 | 2006-07-27 | Michael Beer | Synbiotic combination |
US7101553B2 (en) * | 2000-03-01 | 2006-09-05 | Nestec S.A. | Immune response enhancement methods |
US7101565B2 (en) * | 2002-02-05 | 2006-09-05 | Corpak Medsystems, Inc. | Probiotic/prebiotic composition and delivery method |
US7172777B2 (en) * | 2003-09-18 | 2007-02-06 | Pm-International Ag | Powder for preparation of a probiotic yogurt food |
US7195906B2 (en) * | 1999-01-15 | 2007-03-27 | Enterprise Ireland (Trading As Bioresearch Ireland) | Bifidobacterium in the treatment of inflammatory disease |
US20070196439A1 (en) * | 2006-02-13 | 2007-08-23 | Catani Steven J | Lactose-reduced dairy compositions and related methods |
US20080112942A1 (en) * | 1998-08-07 | 2008-05-15 | Ganeden Biotech, Inc. | Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption |
US20080193485A1 (en) * | 2005-02-15 | 2008-08-14 | Gorbach Sherwood L | Food Containing a Probiotic and an Isolated Beta-Glucan and Methods of Use Thereof |
US20080233092A1 (en) * | 2004-07-22 | 2008-09-25 | Ritter Andrew J | Methods and compositions for treating lactose intolerance |
US20110189148A1 (en) * | 2008-06-25 | 2011-08-04 | Ritter Pharmaceuticals, Inc. | Lactose compositions with decreased lactose content |
US20110223248A1 (en) * | 2007-12-12 | 2011-09-15 | Ritter Pharmaceuticals, Inc. | Methods and compositions for treating lactose intolerance |
Family Cites Families (187)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3048526A (en) | 1958-08-04 | 1962-08-07 | Wander Company | Medicinal tablet |
US3108046A (en) | 1960-11-25 | 1963-10-22 | Smith Kline French Lab | Method of preparing high dosage sustained release tablet and product of this method |
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3718739A (en) | 1971-06-15 | 1973-02-27 | Baxter Laboratories Inc | Treating lactase deficiency with an active lactase |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4532126A (en) | 1982-05-07 | 1985-07-30 | R. P. Scherer Corporation | Masticatory soft elastic gelatin capsules and method for the manufacture thereof |
US4625494A (en) | 1983-04-28 | 1986-12-02 | Pfrimmer & Co. Pharmazeutische Werke Erlangen | Method and apparatus for making mixtures of pharmaceutical liquids |
US4478822A (en) | 1983-05-16 | 1984-10-23 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
JPS6078540U (ja) | 1983-11-05 | 1985-05-31 | アルプス電気株式会社 | キ−ボ−ド |
JPS6163618A (ja) | 1984-09-03 | 1986-04-01 | Akira Yamauchi | 下剤 |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US4839281A (en) | 1985-04-17 | 1989-06-13 | New England Medical Center Hospitals, Inc. | Lactobacillus strains and methods of selection |
US4671953A (en) | 1985-05-01 | 1987-06-09 | University Of Utah Research Foundation | Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics |
GB8601100D0 (en) | 1986-01-17 | 1986-02-19 | Cosmas Damian Ltd | Drug delivery system |
US4919939A (en) | 1986-04-29 | 1990-04-24 | Pharmetrix Corporation | Periodontal disease treatment system |
GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
JP2711095B2 (ja) | 1986-09-27 | 1998-02-10 | ユニチカ株式会社 | ビフイドバクテリウム菌の増殖促進剤の製造法 |
US4800083A (en) | 1986-10-20 | 1989-01-24 | R. P. Scherer Corporation | Sustained release method and product |
NZ222902A (en) | 1986-12-15 | 1990-08-28 | Yakult Honsha Kk | Method for producing galactooligosaccharide |
DE3887179T2 (de) | 1987-03-02 | 1994-06-16 | Brocades Pharma Bv | Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung. |
JP2518663B2 (ja) | 1987-12-24 | 1996-07-24 | 株式会社ヤクルト本社 | ガラクトオリゴ糖含有加工乳の製造法 |
JPH01296935A (ja) | 1988-05-25 | 1989-11-30 | Yakult Honsha Co Ltd | オリゴ糖入りパンの製造法 |
JP2529588B2 (ja) | 1988-05-30 | 1996-08-28 | 株式会社ヤクルト本社 | 複合甘味料 |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
US5032509A (en) | 1988-10-06 | 1991-07-16 | Kabushiki Kaisha Yakult Honsha | Method of preparing galcatooligosaccharide |
US4935243A (en) | 1988-12-19 | 1990-06-19 | Pharmacaps, Inc. | Chewable, edible soft gelatin capsule |
US5149640A (en) | 1988-12-22 | 1992-09-22 | Ajinomoto Co., Inc. | Method for producing galactose transfer products |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5013726A (en) | 1989-09-12 | 1991-05-07 | Ivy Jeffery W | External analgesic lotion containing active ingredients of methyl salicylate and camphor and menthol and method of making such lotion |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
JP2724380B2 (ja) | 1989-12-26 | 1998-03-09 | 松谷化学工業株式会社 | ガラクトオリゴ糖の製造法 |
JP2729406B2 (ja) | 1989-12-27 | 1998-03-18 | 松谷化学工業株式会社 | 難消化性ヘテロ多糖類の製造法 |
US5234828A (en) | 1990-03-16 | 1993-08-10 | Suntory Limited | Process for producing novel heat-resistant β-galactosyltransferase |
FI88856C (fi) | 1990-05-18 | 1997-07-01 | Alko Yhtioet Oy | Foerfarande foer framstaellning av ett fermenterat, huvudsakligen pao havrekli baserat, levande mikroorganismer innehaollande livsmedel |
JP2930370B2 (ja) | 1990-05-25 | 1999-08-03 | 雪印乳業株式会社 | ガラクトオリゴ糖類含有脱脂粉乳の製造方法 |
EP0474230B1 (fr) | 1990-09-05 | 1995-03-15 | Terumo Kabushiki Kaisha | Fibres diététiques insolubles, méthode pour leur production et denrées alimentaires contenant de fibres diététiques |
JP2571734B2 (ja) | 1991-08-23 | 1997-01-16 | 株式会社ヤクルト本社 | 乳酸菌飲料 |
US5225202A (en) | 1991-09-30 | 1993-07-06 | E. R. Squibb & Sons, Inc. | Enteric coated pharmaceutical compositions |
EP0542299B1 (fr) | 1991-11-15 | 1999-08-04 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Polymères contenant des liaisons d'esters utilisés dans des préparations pharmaceutiques |
CA2056167A1 (fr) | 1991-11-25 | 1993-05-26 | James Joseph Miller | Poudre de corps contenant une culture bacterienne vivante |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
AU659896B2 (en) | 1991-12-27 | 1995-06-01 | Matsutani Chemical Industries Co., Ltd. | Feed for livestock which contains galacto-oligosaccharides |
JP3078923B2 (ja) | 1992-04-08 | 2000-08-21 | 塩水港精糖株式会社 | 新規分岐シクロデキストリンおよびその製造方法 |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US5641759A (en) | 1993-05-26 | 1997-06-24 | Purdue Research Foundation | Animal husbandry methods and compositions therefor |
US5439893A (en) | 1993-05-26 | 1995-08-08 | University Of Montana | Methods for the treatment and prevention of diarrhea |
US5840860A (en) | 1993-11-17 | 1998-11-24 | Commonwealth Scientific And Industrial Research Organization | Fatty acid delivery system comprising a hydrolyzable bond |
EP0757555A4 (fr) | 1994-01-14 | 1999-04-07 | Lee Shahinian Jr | Methode assurant une anesthesie corneenne prolongee et etendue |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
FR2723963B1 (fr) | 1994-08-31 | 1997-01-17 | Gervais Danone Co | Preparation de produits fermentes par streptococcus thermophilus, enrichis en galacto-oligosaccharides et en beta-galactosidase |
US5733575A (en) | 1994-10-07 | 1998-03-31 | Bpsi Holdings, Inc. | Enteric film coating compositions, method of coating therewith, and coated forms |
US5871776A (en) | 1995-01-31 | 1999-02-16 | Mehta; Atul M. | Controlled-release nifedipine |
DE19516952A1 (de) | 1995-05-12 | 1996-11-14 | Hoechst Ag | Verfahren zur enzymatischen Galactosylierung von Mono- und Oligosacchariden |
US5827526A (en) | 1995-07-11 | 1998-10-27 | Abbott Laboratories | Use of indigestible oligosaccharides to prevent gastrointestinal infections and reduce duration of diarrhea in humans |
US5733556A (en) | 1995-10-18 | 1998-03-31 | Akzo Nobel N.V. | Newcastle disease virus combination vaccine |
US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
IL127378A (en) | 1996-06-06 | 2003-07-31 | Bifodan As | Enteric coating for an oral preparation |
US5861174A (en) | 1996-07-12 | 1999-01-19 | University Technology Corporation | Temperature sensitive gel for sustained delivery of protein drugs |
JPH10108647A (ja) | 1996-10-08 | 1998-04-28 | Meiji Seika Kaisha Ltd | 胃切除術後患者用ミネラル補給材 |
JP4008974B2 (ja) | 1996-12-12 | 2007-11-14 | 森永乳業株式会社 | ビフィズス菌増殖促進組成物及びその用途 |
ES2212816T3 (es) | 1996-12-20 | 2004-08-01 | NUTRINOVA NUTRITION SPECIALTIES & FOOD INGREDIENTS GMBH | Procedimiento para el refuerzo del poder edulcorante y para el mejoramiento del sabor de una mezcla de materiales edulcorantes muy intensos. |
DE19701382A1 (de) | 1997-01-16 | 1998-07-23 | Nutricia Nv | Kohlenhydratmischung |
US5906982A (en) | 1997-03-31 | 1999-05-25 | Abbott Laboratories | Nutritional formulations containing Lacto-N-neoTetraose |
AU754615B2 (en) | 1997-07-05 | 2002-11-21 | Australasian Food Group Pty Ltd | Frozen dessert |
US6919314B1 (en) | 1998-06-17 | 2005-07-19 | New Zealand Dairy Board | Bioactive whey protein hydrolysate |
UA73092C2 (uk) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
DE19836339B4 (de) | 1998-08-11 | 2011-12-22 | N.V. Nutricia | Kohlenhydratmischung |
US6461607B1 (en) | 1998-08-24 | 2002-10-08 | Ganeden Biotech, Inc. | Probiotic, lactic acid-producing bacteria and uses thereof |
US6139875A (en) | 1998-09-29 | 2000-10-31 | Eastman Chemical Company | Aqueous enteric coating composition and low gastric permeability enteric coating |
NL1010770C2 (nl) | 1998-12-09 | 2000-06-13 | Nutricia Nv | Preparaat dat oligosacchariden en probiotica bevat. |
IT1304170B1 (it) | 1998-12-15 | 2001-03-08 | Novartis Nutrition Ag | Composti organici |
US6572871B1 (en) | 1999-01-06 | 2003-06-03 | W. Edward Church | Pain treatment method and apparatus using heating wrap and analgesic cream |
US6258380B1 (en) | 1999-03-05 | 2001-07-10 | Banner Pharmacaps, Inc. | Chewable soft capsule |
AU5844899A (en) | 1999-04-08 | 2000-11-14 | Airudin S. Khan | Composition, containing sublimed sulfur, for the treatment of lactose intolerance |
JP4273277B2 (ja) | 1999-06-30 | 2009-06-03 | 大塚製薬株式会社 | オリゴ糖補給組成物 |
US6833260B1 (en) * | 1999-10-08 | 2004-12-21 | Protein Scientific, Inc. | Lactose hydrolysis |
US6599882B1 (en) | 1999-11-05 | 2003-07-29 | Joseph A. Rogoff | Secretin and secretin pharmaceuticals for treating lactose intolerance |
DE19958985A1 (de) | 1999-12-07 | 2001-06-13 | Nutricia Nv | Oligosaccharidmischung |
EP1062873A1 (fr) | 1999-12-13 | 2000-12-27 | N.V. Nutricia | Aliment amélioré pour bébés, hydrolysat de protéines utilisables dans un tel aliment pour bébés, et procédé de préparation de cet hydrolysat |
DE19962427A1 (de) | 1999-12-22 | 2001-07-12 | Nutrinova Gmbh | Verkapselte multifunktionelle, biologisch aktive Nahrungsmittelkomponente, Verfahren zu ihrer Herstellung und ihre Anwendung |
US6420473B1 (en) | 2000-02-10 | 2002-07-16 | Bpsi Holdings, Inc. | Acrylic enteric coating compositions |
TWI265008B (en) | 2000-02-17 | 2006-11-01 | Wyeth Corp | Nutritional formulation comprising oligofructose and sialyllactose |
EP1175905A1 (fr) | 2000-07-24 | 2002-01-30 | Societe Des Produits Nestle S.A. | Composition nutritive |
WO2002018614A1 (fr) | 2000-08-30 | 2002-03-07 | Amano Enzyme Inc. | Methode visant a augmenter le rendement d'oligosaccharides contenant $g(a)-galactosyle et compositions anti-candida |
GB2369777B (en) | 2000-10-05 | 2004-10-27 | St Ivel Ltd | Food products with antimicrobial lactic acid bacteria |
US7214370B2 (en) | 2000-12-18 | 2007-05-08 | Probiohealth, Llc | Prebiotic and preservative uses of oil-emulsified probiotic encapsulations |
FI109602B (fi) | 2001-01-25 | 2002-09-13 | Valio Oy | Probioottiyhdistelmä |
US20030185811A1 (en) | 2001-02-06 | 2003-10-02 | Steve Teasdale | Herbal extract and preparation thereof |
EP1243273A1 (fr) | 2001-03-22 | 2002-09-25 | Societe Des Produits Nestle S.A. | Composition contenant un agent prebiotique pour le traitement d'inflammation et d'activation anormal des agents immunitaires non-spécifiques |
JP3921175B2 (ja) | 2001-04-02 | 2007-05-30 | わかもと製薬株式会社 | 口腔内疾患の予防及び/又は治療用組成物 |
US20030017192A1 (en) | 2001-06-19 | 2003-01-23 | Hanny Kanafani | Process for producing extended shelf-life ready-to-use milk compositions containing probiotics |
US6884445B2 (en) | 2001-12-20 | 2005-04-26 | N.V. Nutricia | Matrix-forming composition containing pectin |
US6989166B2 (en) | 2001-12-20 | 2006-01-24 | N.V. Nutricia | Soft drink replacer |
KR20030064030A (ko) | 2002-01-25 | 2003-07-31 | 주식회사 푸코 | 위액 및 담즙산에 대한 내성이 높아 장내 생존력이 우수한한국인 분변 유래 유용 프로바이오틱 생균 및 그의 용도 |
DE20202562U1 (de) * | 2002-02-19 | 2002-05-23 | Orthomol Pharmazeutische Vertr | Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika |
FR2838452B1 (fr) | 2002-04-10 | 2004-07-09 | Eurodia Ind | Procede de production en continu de galacto oligosaccharides |
SE0201214D0 (sv) | 2002-04-23 | 2002-04-23 | Jafar Mahdavi | Multicultural fermented yoghurt |
CN100528169C (zh) | 2002-05-31 | 2009-08-19 | 天野酶株式会社 | 抗炎剂、变应性疾病预防剂或改善剂及功能性食品 |
BR0311645A (pt) | 2002-06-07 | 2005-02-22 | Dzucker Ag Mannheim Ochsenfurt | Isomalte de galactosila - procedimento para sua produção e emprego |
EP1374878A1 (fr) | 2002-06-20 | 2004-01-02 | N.V. Nutricia | Méthode et composition pour éviter ou améliorer les symptômes de malabsorption du tractus gastrointestinal |
US20090022852A1 (en) | 2002-06-21 | 2009-01-22 | Dnp Canada Inc. | Liquid Compositions Comprising Non-Digestible Oligosaccharides and Green Tea Catechins |
DE60330781D1 (de) * | 2002-08-06 | 2010-02-11 | Danisco | Anwendung von lactobacillus zur herstellung von exopolysacchariden in nahrungsmittel und pharmazeutische zusammensetzungen |
FI119429B (fi) | 2002-09-17 | 2008-11-14 | Danisco | Hiilihydraattien uusi käyttö ja koostumukset |
GB0229015D0 (en) | 2002-12-12 | 2003-01-15 | Novartis Nutrition Ag | New Compound |
US20040265291A1 (en) * | 2003-01-24 | 2004-12-30 | Flora Technology Inc. | Compositions and methods for restoring bacterial flora |
US7166451B1 (en) | 2003-02-24 | 2007-01-23 | The Ohio State University | Immobilization of enzyme on a fibrous matrix |
FI20030610A0 (fi) | 2003-04-22 | 2003-04-22 | Raisio Benecol Oy | Syötävä tuote |
US20040213828A1 (en) | 2003-04-23 | 2004-10-28 | Smith David J. | Pain relief lollipop compositions and methods |
US20040265279A1 (en) | 2003-05-08 | 2004-12-30 | Timothy Dinan | Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic pitiuitary-adrenal axis over-activity |
US7291607B2 (en) | 2003-05-20 | 2007-11-06 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Isomaltooligosaccharides from Leuconostoc as neutraceuticals |
WO2004112509A2 (fr) | 2003-06-23 | 2004-12-29 | Nestec S.A. | Formule nutritionnelle pour fonction de barriere intestinale optimale |
JP4384656B2 (ja) | 2003-06-30 | 2009-12-16 | クラサド インコーポレイテッド | 新規のガラクトシダーゼ酵素活性を生じさせるビフィドバクテリウムビフィダムの新規株 |
JP2007527400A (ja) | 2003-07-15 | 2007-09-27 | ネステク ソシエテ アノニム | 高繊維高カロリーの液状又は粉末状栄養組成物 |
KR101095712B1 (ko) | 2003-08-21 | 2011-12-20 | 오츠카 세이야쿠 가부시키가이샤 | 점막 면역 부활 작용을 갖는 유산균 |
GB0321996D0 (en) | 2003-09-19 | 2003-10-22 | Novartis Nutrition Ag | Organic compounds |
GB0322358D0 (en) | 2003-09-24 | 2003-10-22 | Bioprogress Technology Ltd | Improvements in powder compaction and enrobing |
AU2004280375B2 (en) | 2003-10-02 | 2008-05-15 | Nestec S.A. | Prebiotic effect analysis |
PT1721612E (pt) | 2003-10-24 | 2009-09-02 | Nutricia Nv | Oligossacarídeos imunomoduladores |
PL1675481T3 (pl) | 2003-10-24 | 2009-03-31 | Nutricia Nv | Kompozycja synbiotyczna dla niemowląt |
US6936598B2 (en) | 2003-11-21 | 2005-08-30 | Hill's Pet Nutrition, Inc. | Composition and method |
US20050119222A1 (en) | 2003-12-01 | 2005-06-02 | The Iams Company | Compositions comprising fermentable fiber which are adapted for use by a companion animal and kits and methods of their use |
EP1597978A1 (fr) | 2004-05-17 | 2005-11-23 | Nutricia N.V. | Synergie de GOS et polyfructose |
EP1600060A1 (fr) | 2004-05-25 | 2005-11-30 | Cognis IP Management GmbH | Composition orale et/ou topique contenant des prébiotiques et acides gras |
EP1614357A1 (fr) | 2004-07-10 | 2006-01-11 | Cognis IP Management GmbH | complément alimentaire contenant des prébiotiques et des acides gras |
EP1773364B1 (fr) | 2004-07-28 | 2008-10-01 | Abbott Laboratories | Compositions nutritives et procedes pour traiter ou prevenir l'osteoporose |
US7435431B2 (en) | 2004-07-28 | 2008-10-14 | Abbott Laboratories | Method for controlling body weight in estrogen-insufficient women |
US20060034993A1 (en) | 2004-08-10 | 2006-02-16 | Katrin Saelzer | Compositions for improved mouthfeel in reduced-sugar or sugar-free foodstuffs and associated methods and articles therefrom |
EP1629727A1 (fr) | 2004-08-24 | 2006-03-01 | N.V. Nutricia | Composition comprenant des polysaccharides fermentescicles |
ATE361101T1 (de) | 2004-08-24 | 2007-05-15 | Nutricia Nv | Nahrungszusammensetzung die unverdauliche oligosaccharide enthält |
EP1811867A2 (fr) | 2004-11-12 | 2007-08-01 | N.V. Nutricia | Composition alimentaire comprenant une fraction protéique et une fraction lipidique pour l'atténuation rapide d'une réaction inflammatoire |
CN101098633B (zh) | 2004-11-12 | 2011-07-27 | N·V·努特里奇亚 | 用于婴儿的过渡液体营养物 |
EP1825857A1 (fr) | 2004-11-22 | 2007-08-29 | Sunstar Inc. | Agent visant a ameliorer le temps de transit maximum a travers le tube digestif, agent visant a ameliorer le temps de transit a travers le tube digestif et agent prophylactique pour le cancer du colon |
CA2532062A1 (fr) | 2005-01-14 | 2006-07-14 | Nutrinor Cooperative Agro-Alimentaire Du Saguenay Lac St-Jean | Composition alimentaire pour maintien et retablissement des fonctions digestives |
RU2442438C2 (ru) | 2005-02-21 | 2012-02-20 | Нестек С.А. | Смесь олигосахаридов |
EP2805625B2 (fr) | 2005-02-28 | 2022-11-23 | N.V. Nutricia | Composition nutritionnelle avec prébiotiques et probiotiques |
US20060240148A1 (en) | 2005-04-13 | 2006-10-26 | The Dannon Company, Inc. | High-fiber dairy product |
ATE471665T1 (de) | 2005-04-21 | 2010-07-15 | Nutricia Nv | Nahrungsergänzungsmittel für hiv-patienten |
EP1714562A1 (fr) | 2005-04-22 | 2006-10-25 | N.V. Nutricia | Procédé de séchage d'oligosaccahrides d'acide uronique |
DE202005009120U1 (de) | 2005-06-10 | 2005-11-10 | Peterik, Josef | Bifidoaktiver probiotischer Joghurt |
HUP0500582A1 (hu) | 2005-06-13 | 2007-08-28 | Csaba Jozsef Dr Jaszberenyi | Szinergetikus élettani hatású élelmiszerek, élelmiszer-adalékok és táplálék-kiegészítõk vagy takarmányadalékok |
AT501919B1 (de) | 2005-06-14 | 2008-09-15 | Erber Ag | Probiotischer, gesundheits- bzw. leistungsfördernder futtermittel- und/oder trinkwasserzusatz für tiere sowie seine verwendung |
DE102005033630A1 (de) | 2005-07-19 | 2007-01-25 | Humana Gmbh | Calcium-Peptid-Komponente |
FR2889958A1 (fr) | 2005-08-25 | 2007-03-02 | Lyoct Sa Lab | Utilisation d'un symbiotique pour le traitement de la dermatite atopique |
DE102005046237A1 (de) | 2005-09-28 | 2007-04-05 | Südzucker Aktiengesellschaft Mannheim/Ochsenfurt | Buttersäureester von Kohlenhydraten und Kohlenhydratpolyolen |
EP1776877A1 (fr) | 2005-10-21 | 2007-04-25 | N.V. Nutricia | Méthode de stimulation de la flore intestinale |
GB0522740D0 (en) | 2005-11-08 | 2005-12-14 | Clasado Inc | Process for the production of oligosaccharides |
US20070134391A1 (en) | 2005-11-23 | 2007-06-14 | The Coca-Cola Company | High-Potency Sweetener Composition for Treatment and/or Prevention of Autoimmune Disorders and Compositions Sweetened Therewith |
RU2450815C2 (ru) | 2005-12-16 | 2012-05-20 | Н.В. Нютрисиа | Применение растворимых пищевых волокон против мышечной атрофии |
EP1832179B1 (fr) | 2005-12-20 | 2018-11-07 | N.V. Nutricia | Composition d'hydrates de carbone et réponse glycémique réduite |
EP1803358A1 (fr) | 2005-12-28 | 2007-07-04 | Laboratorios Ordesa, S.L | Formule à effet immunologique pour nourrisson. |
WO2007101675A1 (fr) | 2006-03-07 | 2007-09-13 | Nestec S.A. | Mélange synbiotique |
CA2645472C (fr) | 2006-03-10 | 2015-09-15 | N.V. Nutricia | Utilisation de saccharides non digestibles pour assurer a un nouveau-ne le meilleur depart dans la vie |
DK1996156T3 (en) | 2006-03-13 | 2017-02-20 | Lentikat's A S | A unit for the industrial production of biocatalysts in the form of enzymes or microorganisms immobilized in polyvinyl alcohol gel |
WO2007124596A1 (fr) | 2006-05-02 | 2007-11-08 | National Research Council Of Canada | ALPHA-1,4-GALACTOSYLTRANSFÉRASE (CgtD) PROVENANT DE CAMPYLOBACTÈRE JEJUNI |
EP2012596A1 (fr) | 2006-05-03 | 2009-01-14 | Anidral S.R.L. | Composition symbiotique comprenant des polysaccharides non digestibles et des bifidobacteries qui les metabolisent et ses utilisations |
WO2007138905A1 (fr) | 2006-05-30 | 2007-12-06 | Ensuiko Sugar Refining Co., Ltd. | Composition supprimant les éosinophiles intestinaux |
CN101095698B (zh) | 2006-06-26 | 2010-12-01 | 青岛东海药业有限公司 | 酪酸梭菌防治便臭毒素引起的相关症状和疾病的用途 |
CN101926831A (zh) | 2006-06-26 | 2010-12-29 | 青岛东海药业有限公司 | 凝结芽胞杆菌在制备防治便臭和便臭中毒综合征组合物制剂中的应用 |
AU2007280272A1 (en) | 2006-08-04 | 2008-02-07 | Shs International Ltd | Protein free formula |
EP1887017A1 (fr) | 2006-08-09 | 2008-02-13 | Friesland Brands B.V. | Carbohydrates prébiotiques |
EP1897449A1 (fr) | 2006-09-09 | 2008-03-12 | Cognis IP Management GmbH | Compositions buccales et/ou topiques |
SI2076271T1 (sl) | 2006-10-02 | 2011-12-30 | Friesland Brands Bv | Inhibicija toksinov kolere z galatooligosaharidi (GOS) |
WO2008054193A1 (fr) | 2006-11-02 | 2008-05-08 | N.V. Nutricia | Produits alimentaires contenant des oligomères à base de saccharide |
US20080254166A1 (en) | 2007-01-25 | 2008-10-16 | Potter Susan M | Food Additives Containing Combinations of Prebiotics and Probiotics |
WO2008103023A1 (fr) | 2007-02-20 | 2008-08-28 | N.V. Nutricia | Colostrum sélectionné pour le traitement de troubles de la fonction barrière intestinale |
EP2117355B1 (fr) | 2007-03-13 | 2017-04-26 | N.V. Nutricia | Procédé permettant d'améliorer des aptitudes avec une composition comprenant un saccharide non digestible |
PT103714B (pt) | 2007-04-11 | 2020-07-28 | 73100 - Setenta E Três Mil E Cem, Lda. | Processo para a obtenção de um polímero à base de galactose |
WO2008128345A1 (fr) | 2007-04-20 | 2008-10-30 | National Research Council Of Canada | Versions de génie génétique d'enzymes cgtb (β-1,3-galactosyltransférase) à propriétés enzymatiques améliorées |
EP1988096A1 (fr) | 2007-04-26 | 2008-11-05 | Laboratorios Ordesa, S.L | Procédé pour la préparation d'une poudre de galactooligosaccharides |
BRPI0811451A2 (pt) | 2007-05-04 | 2014-11-04 | Alimentary Health Ltd | Exopolissacarídeo |
ITMI20071214A1 (it) | 2007-06-15 | 2008-12-16 | S I I T Srl Servizio Internazi | Composizioni a base di componenti prebiotici ed immunogenici per la prevenzione e il trattamento di disturbi gastroenterici da disbiosi e/o alterazioni della normale flora intestinale |
WO2008153377A1 (fr) | 2007-06-15 | 2008-12-18 | N.V. Nutricia | Nutrition avec une bifidobactérie non viable et un oligosaccharide non digestible |
WO2008156354A1 (fr) | 2007-06-21 | 2008-12-24 | N.V. Nutricia | Modulation de la flore intestinale chez des patients vih |
ATE498325T1 (de) | 2007-07-06 | 2011-03-15 | Nutricia Nv | Verwendung von probiotika und ballaststoffen bei diarrhö |
EP2030623A1 (fr) | 2007-08-17 | 2009-03-04 | Nestec S.A. | Prévention et/ou traitement de troubles métaboliques par la modulation de la quantité d'entérobactéries |
US9139856B2 (en) | 2008-03-12 | 2015-09-22 | Tata Chemicals Ltd. | Process for production of galactooligosaccharides (GOS) |
CN101366734A (zh) | 2008-06-18 | 2009-02-18 | 辽宁大生药业有限公司 | 合生素药物组合物 |
CN101396048A (zh) | 2008-11-25 | 2009-04-01 | 内蒙古蒙牛乳业(集团)股份有限公司 | 一种富含低聚半乳糖奶的生产方法 |
SG2014014435A (en) | 2009-02-24 | 2014-07-30 | Ritter Pharmaceuticals Inc | Prebiotic formulations and methods of use |
AU2010223965A1 (en) | 2009-03-13 | 2011-10-06 | Dsm Food Specialties Usa Inc. | Prebiotic oligosaccharides |
AU2009347008B2 (en) | 2009-05-27 | 2013-08-15 | Clasado Limited | Method of preventing diarrhoea |
IT1395068B1 (it) | 2009-08-07 | 2012-09-05 | Inalco Spa | Processo per la produzione di galatto-oligosaccaridi ultrapuri |
US20130316972A1 (en) | 2010-02-17 | 2013-11-28 | Ritter Pharmaceuticals, Inc. | Prebiotic Formulations and Methods of Use |
WO2011137249A1 (fr) | 2010-04-28 | 2011-11-03 | Ritter Pharmaceuticals, Inc. | Formulations prébiotiques et méthodes d'utilisation |
-
2005
- 2005-07-22 WO PCT/US2005/026095 patent/WO2006012536A2/fr active Application Filing
- 2005-07-22 US US11/632,289 patent/US20080126195A1/en not_active Abandoned
-
2008
- 2008-03-26 US US12/055,936 patent/US9226933B2/en not_active Expired - Fee Related
Patent Citations (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3627583A (en) * | 1969-04-29 | 1971-12-14 | Sucrest Corp | Direct compression vehicles |
US4656066A (en) * | 1982-12-20 | 1987-04-07 | Warner-Lambert Company | Apparatus and method for sealing capsules |
US4629694A (en) * | 1983-07-12 | 1986-12-16 | Cornell Research Foundation, Inc. | Detecting and distinguishing between plasminogen activators |
US4888171A (en) * | 1984-04-18 | 1989-12-19 | Morinaga Milk Industry Co., Ltd. | Granular product of dried microorganism cells and manufacturing method therefor |
US4987150A (en) * | 1987-06-26 | 1991-01-22 | Kabushiki Kaisha Vitamin Kenkyusho | Agent for inhibiting binding of 5-dihydro-testosterone with androgen receptor as well as process for obtaining same |
US4806368A (en) * | 1987-09-16 | 1989-02-21 | Reddy Malireddy S | Shelf life and subsequent growth of lactobacillus acidophilus, propionibacterium shermanii and leuconostoc citrovorum in dietary fiber based supplement preparation |
US4959234A (en) * | 1988-11-17 | 1990-09-25 | Electric Power Research Institute | Method for improving the taste, texture and mouth feel of a liquid dairy product and for concentrating same |
US5219842A (en) * | 1989-08-29 | 1993-06-15 | Nihon Shokuhin Kako Co., Ltd. | Method of improving intestinal floras |
US5716615A (en) * | 1992-02-10 | 1998-02-10 | Renata Maria Anna Cavaliere Vesely | Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use |
US5550106A (en) * | 1994-03-04 | 1996-08-27 | Bristol-Myers Squibb Company | Low buffer nutritional composition |
US5709857A (en) * | 1994-05-26 | 1998-01-20 | Dibra S.P.A. | Lactobacillus strains of human origin, their compositons and uses thereof |
US5952021A (en) * | 1994-06-14 | 1999-09-14 | Recordati S.A. Chemical And Pharmaceutical Company | Stabilized biologically active compounds contained in coated microgranules which can be suspended in alimentary fluids |
US5744134A (en) * | 1994-10-28 | 1998-04-28 | Metagenics, Inc. | Immunoglobulin and fiber-containing composition for human gastrointestinal health |
US6241983B1 (en) * | 1994-10-28 | 2001-06-05 | Metagenics, Inc. | Bacteria-and fiber-containing composition for human gastrointestinal health |
US5852021A (en) * | 1995-03-28 | 1998-12-22 | Ferrer Internacional, S.A. | Polymorph B of 1-(diphenylmethyl)-4- 3-(2-phenyl-1,3-dioxolan-2-YL) propyl! piperazine |
US6221350B1 (en) * | 1996-03-20 | 2001-04-24 | The University Of New South Wales | Enhancement of microbial colonisation of the gastrointestinal tract |
US5895648A (en) * | 1996-12-23 | 1999-04-20 | Sitia-Yomo S.P.A. | Composition for feed use comprising lyophilized live lactic bacteria |
US6093425A (en) * | 1997-11-21 | 2000-07-25 | Princeton Nutrition, L.L.C. | Complete nutritional milk compositions and products |
US5952205A (en) * | 1998-02-06 | 1999-09-14 | Neose Technologies, Inc. | Process for processing sucrose into glucose and fructose |
US6423833B1 (en) * | 1998-05-05 | 2002-07-23 | Steven J. Catani | Functional sugar polymers from inexpensive sugar sources and apparatus for preparing same |
US20020034496A1 (en) * | 1998-07-07 | 2002-03-21 | Andrew J. Ritter | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
US20060104965A1 (en) * | 1998-07-07 | 2006-05-18 | Ritter Andrew J | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
US20080112941A1 (en) * | 1998-07-07 | 2008-05-15 | Ritter Andrew J | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
US7029702B2 (en) * | 1998-07-07 | 2006-04-18 | Ritter Natural Sciences Llc | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
US20130034601A1 (en) * | 1998-07-07 | 2013-02-07 | Ritter Pharmaceuticals, Inc. | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
US20080112942A1 (en) * | 1998-08-07 | 2008-05-15 | Ganeden Biotech, Inc. | Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption |
US6471999B2 (en) * | 1998-09-08 | 2002-10-29 | Nestec S.A. | Milk-based powder for pets |
US7195906B2 (en) * | 1999-01-15 | 2007-03-27 | Enterprise Ireland (Trading As Bioresearch Ireland) | Bifidobacterium in the treatment of inflammatory disease |
US6835376B1 (en) * | 1999-03-11 | 2004-12-28 | Nestec S.A. | Lactobacillus paracasei strain for preventing diarrhea caused by pathogenic bacteria |
US20040161422A1 (en) * | 1999-04-30 | 2004-08-19 | Natarajan Ranganathan | Nutritional compositions comprising probiotics |
US6468525B1 (en) * | 1999-08-10 | 2002-10-22 | Renew Life, Inc. | Probiotic formulation |
US7101553B2 (en) * | 2000-03-01 | 2006-09-05 | Nestec S.A. | Immune response enhancement methods |
US6368641B1 (en) * | 2000-04-28 | 2002-04-09 | Hartz International Inc. | Lactic acid bacteria and food products |
US6929793B2 (en) * | 2000-11-14 | 2005-08-16 | Nestec S.A. | Nutritional composition for treating an immune condition |
US6797266B2 (en) * | 2000-12-18 | 2004-09-28 | Probiohealth | Probiotic composition containing Lactobacillus casei strain ATCC PTA-3945 |
US6706287B2 (en) * | 2001-05-15 | 2004-03-16 | Kibow Biotech Inc. | Prebiotic and probiotic compositions and methods for their use in gut-based therapies |
US20030147995A1 (en) * | 2001-08-31 | 2003-08-07 | Ronald Koss | Nutritional frozen dessert and methods of manufacture |
US20050079244A1 (en) * | 2001-11-12 | 2005-04-14 | Giffard Catriona Julie | Foodstuff |
US7101565B2 (en) * | 2002-02-05 | 2006-09-05 | Corpak Medsystems, Inc. | Probiotic/prebiotic composition and delivery method |
US20050074442A1 (en) * | 2002-03-13 | 2005-04-07 | Natarajan Ranganathan | Compositions and methods for augmenting kidney function |
US20040057943A1 (en) * | 2002-06-28 | 2004-03-25 | Jordi Xaus Pey | Probiotic strains, a process for the selection of them, compositions thereof, and their use |
US6960341B2 (en) * | 2002-09-06 | 2005-11-01 | Alfa Wassermann S.P.A. | Bifidobacteria and preparations containing them |
US20060141097A1 (en) * | 2002-10-22 | 2006-06-29 | Mingruo Guo | Symbiotic food products comprising oats and methods for manufacturing the same |
US20050180962A1 (en) * | 2003-01-30 | 2005-08-18 | Eyal Raz | Inactivated probiotic bacteria and methods of use thereof |
US20060165670A1 (en) * | 2003-04-08 | 2006-07-27 | Michael Beer | Synbiotic combination |
US7172777B2 (en) * | 2003-09-18 | 2007-02-06 | Pm-International Ag | Powder for preparation of a probiotic yogurt food |
US20080233092A1 (en) * | 2004-07-22 | 2008-09-25 | Ritter Andrew J | Methods and compositions for treating lactose intolerance |
US20060093592A1 (en) * | 2004-10-04 | 2006-05-04 | Nutracea | Synbiotics |
US20080193485A1 (en) * | 2005-02-15 | 2008-08-14 | Gorbach Sherwood L | Food Containing a Probiotic and an Isolated Beta-Glucan and Methods of Use Thereof |
US20070196439A1 (en) * | 2006-02-13 | 2007-08-23 | Catani Steven J | Lactose-reduced dairy compositions and related methods |
US20110223248A1 (en) * | 2007-12-12 | 2011-09-15 | Ritter Pharmaceuticals, Inc. | Methods and compositions for treating lactose intolerance |
US20110189148A1 (en) * | 2008-06-25 | 2011-08-04 | Ritter Pharmaceuticals, Inc. | Lactose compositions with decreased lactose content |
Non-Patent Citations (7)
Title |
---|
Ansel, H.C., Allen, Jr., L.V., Popovich, N.G. (1999) PHARMACEUTICAL DOSAGE FORMS AND DRUG DELIVERY SYSTEMS. Published by Lippincott Williams & Wilkins, p. 60-100. * |
De Vries, W., Stouthamer, A.H. (1968) Fermentation of Glucose, Lactose, Galactose, Mannitol, and Xylose by Bifidobacteria. Journal of Bacteriology, vol. 96, no. 2, p. 472-478. * |
Hertzler, S.R., Savaiano, D.A. (1996) Colonic adaptation to daily lactose feeding in lactose maldigesters reduces lactose intolerance. American Journal of Clinical Nutrition, vol. 64, p. 232-236. * |
Jiang, T., Savaiano, D.A. (1997) In Vitro Lactose Fermentation by Human Colonic Bacteria is Modified by Lactobacillus acidophilus Supplementation. Journal of Nutrition, vol. 127, p. 1489-1495. * |
Khan, M.A. (2004) Lactagen Hopes Search Test Does a Body Good. Retrieved on 3/31/2014 [online]. Retrieved from Direct Marketing News, from the internet * |
Remington's THE SCIENCE AND PRACTICE OF PHARMACY, 19TH Edition, editor Alfonso R. Gennaro, published by Mack Publishing Company (1995) p. 1396, 1406-1413 and 1617-1620. * |
Scrimshaw, N.S., Murray, E.B. (1988) Adaptation of lactose-maldigesting individuals to milk and milk products. American Journal of Clinical Nutrition, vol. 48 (suppl), p. 1118-1119. * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080112941A1 (en) * | 1998-07-07 | 2008-05-15 | Ritter Andrew J | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
US7879363B2 (en) | 1998-07-07 | 2011-02-01 | Ritter Pharmaceuticals, Inc. | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
US20110086093A1 (en) * | 1998-07-07 | 2011-04-14 | Ritter Pharmaceuticals, Inc. | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
US20080233092A1 (en) * | 2004-07-22 | 2008-09-25 | Ritter Andrew J | Methods and compositions for treating lactose intolerance |
US9226933B2 (en) | 2004-07-22 | 2016-01-05 | Ritter Pharmaceuticals, Inc. | Methods and compositions for treating lactose intolerance |
US20110223248A1 (en) * | 2007-12-12 | 2011-09-15 | Ritter Pharmaceuticals, Inc. | Methods and compositions for treating lactose intolerance |
US20110189148A1 (en) * | 2008-06-25 | 2011-08-04 | Ritter Pharmaceuticals, Inc. | Lactose compositions with decreased lactose content |
US8492124B2 (en) | 2009-02-24 | 2013-07-23 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
US8486668B2 (en) | 2009-02-24 | 2013-07-16 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
US8785160B2 (en) | 2009-02-24 | 2014-07-22 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
US20110236480A1 (en) * | 2009-02-24 | 2011-09-29 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
US9579340B2 (en) | 2009-02-24 | 2017-02-28 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
US9592248B2 (en) | 2009-02-24 | 2017-03-14 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
US9775860B2 (en) | 2009-02-24 | 2017-10-03 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
US9808481B2 (en) | 2009-02-24 | 2017-11-07 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
US20150328267A1 (en) * | 2010-02-05 | 2015-11-19 | Daniel Henry Wyrobnik | Composition for use in the therapy of lactose intolerance or conditions arising from lactase deficiency |
US11166992B2 (en) * | 2010-02-05 | 2021-11-09 | Vitacare Gmbh & Co. Kg | Composition for use in the therapy of lactose intolerance or conditions arising from lactase deficiency |
Also Published As
Publication number | Publication date |
---|---|
WO2006012536A3 (fr) | 2006-05-26 |
US20080233092A1 (en) | 2008-09-25 |
US9226933B2 (en) | 2016-01-05 |
WO2006012536A2 (fr) | 2006-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6882931B2 (ja) | プレバイオティック製剤および使用方法 | |
US9226933B2 (en) | Methods and compositions for treating lactose intolerance | |
McBEAN et al. | Allaying fears and fallacies about lactose intolerance | |
Costalos et al. | Enteral feeding of premature infants with Saccharomyces boulardii | |
US7141554B2 (en) | Method of treating irritable bowel syndrome | |
Suarez et al. | Review article the treatment of lactose intolerance | |
US20100166721A1 (en) | Probotic compositions and uses thereof | |
US20110165127A1 (en) | Dairy-derived probiotic compositions and uses thereof | |
US7879363B2 (en) | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance | |
US20170189457A1 (en) | Probiotic Sports Nutrition Compositions | |
US20170042950A1 (en) | Materials and methods for improving gastrointestinal health | |
US20110223248A1 (en) | Methods and compositions for treating lactose intolerance | |
Srinivasan et al. | When to suspect lactose intolerance: symptomatic, ethnic, and laboratory clues | |
RU2769312C2 (ru) | Использование молочнокислых бактерий для лечения или профилактики гестационного сахарного диабета | |
WO2024098978A1 (fr) | Produit laitier fermenté à température normale, son procédé de préparation et son utilisation | |
Wood | Sensory evaluation of ice cream made with prebiotic ingredients substituted for sugar | |
Sanders et al. | Use of probiotic yogurts in health and disease | |
ES2929638T3 (es) | Uso de bacterias del ácido láctico para tratar o prevenir la diabetes mellitus gestacional | |
Hunter | Probiotic foods for good health: Yogurt, sauerkraut, and other beneficial fermented foods | |
JP2024513429A (ja) | ビフィズス菌を刺激するための栄養組成物 | |
Intolerance | Food Intolerance | |
Sankar et al. | Health Benefits and Complications Involved in Probiotics | |
Jason Shea et al. | Probiotics–The Ultimate Guide (2020): Probiotics Benefits, Brands, and More | |
TW201043236A (en) | Method of preventing diarrhoea |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: RITTER NATURAL SCIENCES, LLC, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:RITTER, ANDREW J.;REEL/FRAME:020236/0005 Effective date: 20071201 |
|
AS | Assignment |
Owner name: RITTER PHARMACEUTICALS, INC., CALIFORNIA Free format text: CHANGE OF NAME;ASSIGNOR:RITTER NATURAL SCIENCES, LLC;REEL/FRAME:022473/0856 Effective date: 20080912 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: RITTER PHARMACEUTICALS, INC., CALIFORNIA Free format text: ASSIGNEE CHANGE OF ADDRESS;ASSIGNOR:RITTER PHARMACEUTICALS, INC.;REEL/FRAME:037274/0149 Effective date: 20151104 |